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INTRODUCTION
Since the initial description by Silver et al.,1
heparin-induced thrombocytopenia (HIT) has been
recognized as a significant potential complication of
heparin therapy, associated with a risk of throm-
boembolic events such as pulmonary embolism,
stroke, myocardial infarction, and limb loss. The
overall reported range of incidence of HIT after
heparin therapy is from 1% to 30%, depending on
the patient population studied and the method of
diagnosis.2 Thrombosis in association with HIT has
been associated with a mortality rate of about 30%
and a 20% risk of leg amputation.3–5 
Recent studies documented that patients with
HIT have antibodies that are directed against a com-
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plex of heparin and platelet factor 4 (PF4), a protein
that has an extremely high affinity for heparin.6–8
These antibodies then bind platelet Fc receptors and
cause platelet activation, which then leads to throm-
bosis. Several laboratories have developed ELISAs
that use the complex of heparin-PF4 to detect
immunoglobulin G (IgG) antibodies in sera from
patients suspected of having HIT.9,10 The ELISA for
detection of anti-heparin/PF4 antibodies appears to
be more sensitive than the 14C serotonin release
assay and the platelet aggregation test.6,11,12
In a recent study of heparin-induced antibodies
after cardiac surgery, 111 patients were routinely
tested for heparin-induced antibodies using a
heparin/PF4 ELISA.13 Postoperatively, 51% were
positive for heparin-induced antibodies. Although
no thrombotic events attributable to heparin-
induced antibodies occurred, the high incidence of
antibody response suggests that there would be a
potentially increased risk for HIT developing in
these patients should prolonged exposure or subse-
quent re-exposure to heparin be necessary. 
The preceding study raises the concern that the
incidence of heparin-induced antibodies after intra-
operative anticoagulation for peripheral vascular
surgery might also be high when assessed using the
newer, highly sensitive heparin/PF4 ELISA. To
date, this incidence is unknown. The purpose of our
study was to prospectively evaluate the incidence of
heparin-induced antibodies after peripheral vascular
surgery using a sensitive, validated heparin/PF4
ELISA. Additionally, the influence of previous
heparin exposure on antibody formation and the
clinical outcome of these patients are described.
METHODS
The study was conducted under a protocol
approved by the Institutional Review Board and
Human Use Committee. Eligible patients were those
undergoing elective arterial revascularization during
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Fig. 1. Schematic illustration of heparin/PF4 ELISA. Heparin-induced IgG antibodies from
patient plasma bind the complex of heparin and PF4 in ELISA microtiter plate. Heparin-
induced IgG antibodies (if present) are detected after incubation with alkaline phosphatase-
labeled goat anti-human IgG and color development with enzyme substrate.
which heparin anticoagulation would be used.
Patients requiring continued postoperative anticoag-
ulation were not eligible. Fifty-six consecutive
patients were approached to participate in the study,
and 54 were enrolled. Blood samples were obtained
preoperatively for determination of platelet count
and for the heparin/PF4 ELISA. Postoperative
blood samples were obtained to determine platelet
counts with routinely ordered complete blood
counts. Separate blood samples for postoperative
determination of heparin/PF4 ELISA were drawn at
a mean of 14 ± 7.5 (SD) days after surgery.
Heparin/PF4 ELISA. ELISA plate wells
(Corning EZ wash, Corning Glassworks, Corning,
NY) were each coated with 1 m g PF4 (Alexis Corp,
San Diego, Calif) and 0.05 units unfractionated
heparin (Elkins-Sinn, Inc, Cherry Hill, NJ) in 100 m L
0.02 M phosphate-buffered saline, pH 7.4. Plates
were blocked and then incubated with patient plasma
diluted 1:50; IgG antibodies were detected after incu-
bation with alkaline-phosphatase labeled goat anti-
bodies (specific for human IgG) for 1 hour at 37°C
(Fig. 1). Each plate contained pooled plasma (nega-
tive control) and a sample known to be positive for
IgG by platelet aggregation studies. The intra-assay
coefficient of variation for IgG antibodies was <6% at
all antibody levels (ratios) tested. The results were
expressed as the ratio of the optical density (ODR) of
patient plasma to that of normal pooled plasma. A
positive test was one with an ODR ‡ 1.8. An ODR
‡ 1.6 and <1.8 was considered indeterminate. An
ODR <1.6 was considered negative (normal).
Previous heparin/PF4 ELISA validation. In
an earlier validation study of our ELISA, 49 plasma
samples from patients suspected of having HIT were
tested in the ELISA for IgG antibodies and with
platelet-based studies (aggregation or 14C serotonin
release).10 Of the 10 patients who tested positive by
platelet-based methods, all had a positive IgG in the
ELISA. The plasma from an additional 39 patients,
who were suspected of having HIT on clinical
grounds but who had normal platelet aggregation
testing for heparin-induced antibodies, was also
assessed with the heparin/PF4 ELISA. Of the 39
patients, 10 (25.6%) tested positive for HIT by
means of ELISA, suggesting that ELISA is more sen-
sitive than platelet aggregation testing. Plasma sam-
ples from 50 patients who had normal platelet aggre-
gation testing for heparin-induced antibodies were
also evaluated and tested negative for HIT by means
of ELISA in all cases. The absence of false-positive
ELISA in this group suggests high specificity. In
addition, this ELISA was used in a previous study at
our center in which the clinical utility of the assay was
demonstrated in a small series of vascular surgery
patients who were suspected on clinical grounds to
have HIT.15 In that study, all 4 patients meeting the
criteria for the clinical diagnosis of HIT with throm-
bosis tested positive using this heparin/PF4 ELISA.
Data Analysis. Descriptive data are expressed as
the mean ± the standard deviation, unless otherwise
noted. Preliminary sample-size estimates were per-
formed to establish the incidence of heparin-induced
antibodies within a 10% range at the 95% confidence
interval. The incidence of heparin-induced antibod-
ies is expressed with the 95% confidence interval.
Quantitative comparisons of ELISA results (ODR)
were performed with the use of Wilcoxon’s rank
sum test. The difference in platelet counts from
baseline to after surgery for all patients was analyzed
using both a paired t-test and Wilcoxon signed rank
test. Comparisons between groups were 2-tailed.
Significance was determined at the P < .05 level. All
statistical analyses were performed using SPSS statis-
tical software (SPSS version 7.5 for Windows 95,
SPSS, Inc, Chicago, Ill).
RESULTS
Thirty-six men and 18 women (mean age, 67.2 ±
9.7 years) were enrolled. A history of previous heparin
exposure was documented in 22 patients (40.7%).
Surgical procedures performed were carotid endar-
terectomy (in 36 patients), aortic reconstruction (in
11 patients), and infrainguinal bypass (in 7 patients).
The mean intraoperative heparin dose was 9089 ±
3607 international units (IU). Unfractionated porcine
heparin was used in all cases.
Only 1 patient converted from a negative
heparin/PF4 ELISA to a positive heparin/PF4
ELISA after surgery (1.9%, 95% CI = 0.10% –
11.18%; Table I). This patient had no history of
heparin exposure and manifested a postoperative
ELISA OD ratio of 1.8, the lower threshold limit for
an abnormal result. Two patients (3.7%) had a posi-
tive ELISA at baseline and remained positive after
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Table I. Summary of heparin/PF4 ELISA results.








surgery. One of these patients had a documented
prior heparin exposure. Forty-six patients had nega-
tive ELISA results both before and after surgery.
Four patients (7.4%) had 1 indeterminate ELISA
and 1 normal ELISA. In 1 patient (1.9%), both
ELISAs were indeterminate.
Because few patients exceeded the threshold for
an abnormal ELISA result, we also analyzed the over-
all mean change in the quantitative ELISA results for
the entire patient group before and after heparin.
The mean preoperative ELISA ODR was 1.11 ±
0.40, vs. 1.14 ± 0.52 after surgery (P = .67). The
postoperative change from baseline in the ELISA
ODR with no history of heparin exposure (–0.022 ±
0.272) was no different than for those with previous
exposure (+0.042 ± 0.272, P = 0.57 ). When sepa-
rately analyzed according to prior heparin exposure,
the baseline and postoperative ELISA ODRs were
not different (Fig. 2). Similarly, the intraoperative
heparin dose had no effect on the postoperative
change in the ELISA ODR (Fig. 3). The R2 value for
the linear regression line was only 0.027.
For the entire group, the mean platelet count
after surgery decreased from 227,620 ± 78,308 dL
to 185,706 ± 80,842 dL (P <.001). The decrease in
platelet count, expressed as the percent change from
baseline, was not different in patients with prior
heparin exposure (–23.0 ± 18.0%) or without prior
heparin exposure (-18.0 ± 14.0%, P = .46).
Only 1 patient had a thrombotic complication.
Thrombotic occlusion of an infrainguinal bypass graft
developed in this patient, who tested negative for
heparin-induced antibodies before and after surgery. 
DISCUSSION
Although recently published data suggest that
patients undergoing cardiac surgery have a high inci-
dence (51%) of heparin-induced antibodies after
intraoperative heparin anticoagulation,13 we did not
observe a significant incidence (1.9%, 1 patient of 54
initially testing negative for antibodies). Only 1
patient converted from a negative to positive anti-
body status after the use of heparin for intraoperative
anticoagulation during peripheral vascular surgery. A
history of heparin exposure did not influence the
results. There was no change in the ELISA ODR
after intraoperative heparin treatment in patients
with or without a prior exposure to heparin.
There are several potential explanations to
account for the lower incidence of heparin-induced
antibodies observed in the present study as com-
pared with that seen in cardiac surgery patients.13
The heparin dose was higher in Bauer’s study of car-
diac surgery patients, with an intraoperative dose of
300 IU/kg, compared with 100 IU/kg in the pres-
ent study. Others have shown an association
between heparin dose and the incidence of HIT.2
The patients in Bauer’s study all received bovine
heparin, whereas porcine heparin was given to our
patients. In a review comparing the effect of the type
of heparin on the incidence of HIT, estimates from
pooled data show a 1.1% incidence with porcine
heparin and a 2.9% incidence with bovine heparin.14
Another potential reason for the difference in the
incidence of heparin-induced antibodies between
the 2 studies relates to prior heparin exposure.
Although the overall percentage of patients with a
previous heparin exposure was similar in both stud-
ies (Bauer, et al: 31%, present study: 41%), the pre-
operative exposure to heparin documented in the
cardiac surgery series occurred during the same hos-
pitalization, whereas in our study the heparin expo-
sure was always remote (more than 3 months before
surgery). Bauer observed a significant increase in the
incidence of heparin-induced antibodies postopera-
tively in those patients with recent heparin exposure
(68%), compared with those without recent heparin
exposure (46%, P = 0.05).13
Perhaps the most significant difference in method-
ology between the 2 studies is the ELISA technique.
In Bauer’s study, the ELISA plate wells containing
patient’s plasma and the complex of heparin/PF4
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Fig. 2. Box plots of quantitative ELISA results before
and after vascular surgery. Groups are separately analyzed
based on prior heparin exposure. Box plots depict the
25th to 75th percentiles for ODR values within the box.
The horizontal line within the box is the median value.
Extreme values are depicted by arrow bars.
were incubated with a polyvalent antihuman IgG
(Diagnostica Stago, Asnieres Sur Seine, France). The
polyvalent IgG detects human IgG, IgA, and IgM if
present. Moreover, a positive test result does not dis-
tinguish which of the immunoglobulin isotopes is
(are) present. The clinical significance of IgA and IgM
in HIT has been questioned, because platelets lack an
Fc receptor for these isotopes. In our previous
heparin/PF4 ELISA validation study, assays were per-
formed to detect the IgG and IgM isotopes separate-
ly.10 Only 1 patient tested positive for IgM alone. In
a separate series of vascular surgery patients who
received a clinical diagnosis of HIT from our center,
all 4 tested positive for IgG by ELISA, and none were
positive for IgM.15
Another potentially important difference in the 2
ELISA assays is the spectrum of ODR results that is
labeled as indeterminate. In our study, only 4.6% of all
assays performed were interpreted as indeterminate.
In Bauer’s study, 28% of all assays were indetermi-
nate.13 Although their results might represent a wider
distribution of the actual immunologic response to
heparin, the significant proportion of tests that are
neither positive nor negative imposes a potential lim-
itation to the clinical utility of such testing. 
Given the recognition that patients with HIT
have antibodies directed against the complex of
heparin/PF4, the role of laboratory testing for HIT
is changing accordingly. The standard diagnostic test
for HIT in most laboratories is the platelet aggrega-
tion test.
Although this test is simple and can be performed
quickly, its sensitivity has been questioned. Depending
on the reactivity of donor platelets and heparin con-
centration used in the aggregation test, the sensitivity
can range from 29% to 88%.16 The 14C serotonin
release assay appears to be a more sensitive test.7,17 In
this test, the release of 14C serotonin from the platelets
is measured, as opposed to the ability of platelets to
aggregate, because immune complexes can induce
release without causing aggregation. A limitation of
both tests is that they require normal reactivity of the
donor platelets used in the assays. The ELISA for
detection of anti-heparin/PF4 antibodies appears to
be more sensitive than the 14C serotonin release assay
and the platelet aggregation test.6,11,12,15 A kit for the
heparin/PF4 ELISA is now commercially available for
research purposes (Diagnostica Stago, Asnieres Sur
Seine, France).
Despite the greater sensitivity of the ELISA, it is
likely that it will be best used to complement, rather
than replace, aggregation-based testing. Studies
have shown that the ELISA and aggregation-based
testing identify slightly different patient cohorts,
suggesting that other antigens may play a role in
HIT.11 Discrepant results between ELISA and
aggregation-based tests have been observed in 10%
to 20% of patients.18 In some patients with HIT,
antibodies directed against interleukin 8 and neutral
activating peptide 2 have been identified.19 Given
the high sensitivity of the ELISA in comparison with
aggregation-based testing, a rational approach to
laboratory testing would be to perform the ELISA
as the initial test for patients in whom the diagnosis
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Fig. 3. Scatter plot of change in ODR (postoperative ODR minus baseline ODR) as a func-
tion of intraoperative heparin dose. The middle line is the linear regression line for mean val-
ues. Upper and lower lines represent the range of the 95% confidence interval.
of HIT is suspected and reserve aggregation-based
tests for those patients with a negative ELISA and
continued clinical suspicion. 
Although the low incidence of heparin-induced
antibodies demonstrated in the present study is reas-
suring to the vascular surgeon who must use intra-
operative heparin anticoagulation, HIT remains a
risk for patients who require prolonged heparin
treatment. The development of alternative anticoag-
ulants offers a potential solution to this challenging
clinical problem. Potential alternative anticoagulants
include heparinoid (Org 10172), argatroban, and
hirudin and its analogs.
In a limited series of HIT in vascular surgery
from our institution, we continue to observe major
morbidity, including limb loss.15 In that series, all
patients had at least 7 days of continuous intra-
venous heparin therapy before onset of thrombocy-
topenia and thrombotic complications. The inci-
dence of heparin-induced antibodies, as measured
by sensitive ELISA techniques, in vascular surgery
patients requiring prolonged heparin treatment
remains unknown.
In summary, heparin-induced antibodies occur
infrequently after peripheral vascular surgery, despite
what appears to be a significant incidence after cardiac
surgery. The frequently observed, mild degree of
postoperative thrombocytopenia does not appear to
be caused by heparin-induced antibodies. These
results indicate that a standard dose of heparin for
intraoperative anticoagulation during vascular surgery
is not associated with a significant risk of heparin-
induced thrombocytopenia and thrombosis. Whether
a similarly low incidence of heparin-induced antibod-
ies will be observed in vascular surgery patients
requiring prolonged heparin treatment remains to be
studied.
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Dr Michael Sobel (Richmond, Va). Thank you. I am
honored to discuss this fine paper. The phenomenon of
heparin-induced thrombocytopenia has undergone impor-
tant changes in the 10 years since I first presented a paper
at this meeting about management of the devastating
thrombotic complications. First, I think the syndrome has
diminished in frequency, or at least the more severe man-
ifestations have, because we have become more vigilant
and circumspect about how we use heparin.
Secondly, I think our understandings of the biology of
the syndrome have become much clearer, and I think that
Dr John Kelton’s description of this heterogeneous syn-
drome as a pyramid is apt. The broad base of the pyramid is
filled with a large number of patients who may develop a
detectable antibody, but their platelets never become acti-
vated or functionally tagged with immune complexes. A
smaller group in the upper range of the pyramid, perhaps
1% to 5% of patients exposed to heparin, will experience
activation of their platelets by the antibodies and thrombo-
cytopenia. The now old-fashioned platelet aggregation test-
ing results are usually positive in this group. Finally, at the
top of the pyramid, is an even smaller group of patients who
suffer thrombocytopenia and thrombosis, and their results
are uniformly positive with almost all testing methods.
Dr Jackson and his colleagues from Walter Reed and
the University of Texas–Southwestern have presented a
carefully conducted surveillance of the frequency of
heparin-induced thrombocytopenia–type antibodies in
patients undergoing vascular surgery, a survey of the bot-
tom of the pyramid. Now, several other groups have
described a high frequency of antibody positivity in this
asymptomatic group—50% after open heart surgery, 20%
after coronary surgery. His manuscript is as well-written as
his presentation was clear. And the technical methodology
of Dr Jackson and Dr Alving is impeccable.
My first questions regards the assay itself. There are at
least two commercial kits now on the market or coming to
market. What makes his proprietary assay system different
or better? Why not, for example, detect IgM and IgA anti-
bodies, too? There have been bona fide clinical reports of
patients with those kinds of antibodies suffering this syn-
drome. I have also observed in my own practice and from
referrals of these patients that patients who are undergo-
ing more extensive vascular surgery and possibly more
intense activation of their platelets, such as leg bypass graft
or aneurysm surgery, may be more prone to heparin-
induced thrombocytopenia than those experiencing short-
er, less traumatic operations like carotid endarterectomy.
When you consider the 67% of your patients who under-
went carotid endarterectomy, might your results be
skewed or at least not representative of the typical vascular
practice? Also, considering that your patients never
received any postoperative heparin therapy, might that be
an untypical group for most of our practices?
In closing, I would offer only a single caution regard-
ing your final conclusion that heparin-induced thrombo-
cytopenia antibodies occur infrequently. It may be true,
but it will take a longer, deeper look at the syndrome to
know for sure. However, it is just the kind of careful study
that will someday tell us what is the meaning and clinical
significance of a positive antibody test result.
Dr Mark R. Jackson. In response to your question
regarding our ELISA assay, as you correctly point out,
there are assays that are commercially available for research
purposes, and the use of these assays would probably be
the most expeditious way for a laboratory to begin to per-
form these tests. We developed our assay at a time when
these other assays were not available, so for us this was a
matter of necessity rather than practicality. There are a
number of differences in our assay from the Stago kit to
which you referred. Our assay does not detect the IgA 
isotype. Earlier, while we were developing our ELISA, we
did test for the IgM isotype. In these earlier studies we
found that the ELISA was rarely positive for IgM.
Furthermore, given that platelets lack an Fc receptor for
IgM or IgA, a positive result is of uncertain clinical signif-
icance. Regarding your question about the nature and
magnitude of the surgical procedure, this likely does influ-
ence whether one develops the clinical syndrome of
heparin-induced thrombocytopenia and thrombosis.
Patients who have more extensive operation have a greater
production of proinflammatory cytokines. It has been
shown that inflammation promotes platelet Fc receptor
expression. However, I do not think that it has been
shown that antibody production is influenced by the mag-
nitude of surgery. Because our study specifically evaluated
antibody production, and it was low, I think our results
would also apply to patients undergoing surgery of greater
magnitude. Yet, having said that, patients who develop
heparin-induced antibodies and have a significant inflam-
matory response, such as after a major operation, are
probably more likely to develop the clinical syndrome of
HIT with thrombosis than are patients with positive anti-
bodies after surgery of lesser magnitude.
Regarding the use of postoperative heparin, I agree that
the results of this study that indicate a low incidence of
heparin-induced antibodies might not be applicable to a
group of vascular patients that does receive a prolonged
administration of heparin. I do not mean to imply with
this study that vascular patients are not at risk for the clin-
ical syndrome of HIT. In fact, those patients who do
develop HIT are likely to be the ones you indicated, those
receiving continued postoperative heparin.
Thank you.
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DISCUSSION
